Published in Int J Radiat Oncol Biol Phys on February 01, 2004
Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett (2007) 1.62
Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol (2011) 1.35
Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs (2010) 1.25
Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2010) 1.16
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer (2011) 1.10
Radiation oncology in the era of precision medicine. Nat Rev Cancer (2016) 0.97
EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head Neck (2011) 0.93
A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer (2007) 0.91
Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol (2007) 0.91
Molecular biology of head and neck cancer: risks and pathways. Hematol Oncol Clin North Am (2008) 0.91
The phosphatase and tensin homologue deleted on chromosome 10 mediates radiosensitivity in head and neck cancer. Br J Cancer (2010) 0.89
Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag (2007) 0.89
Clinicopathologic analysis of esophageal and cardiac cancers and survey of molecular expression on tissue arrays in Chaoshan littoral of China. World J Gastroenterol (2004) 0.88
Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008. Clin Cancer Res (2009) 0.86
Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 0.86
Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma. Radiat Oncol (2012) 0.82
Initial evidence for Sec62 as a prognostic marker in advanced head and neck squamous cell carcinoma. Oncol Lett (2016) 0.81
EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. Pharmacol Ther (2015) 0.79
Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Clin Cancer Res (2014) 0.78
The Expression of NMDA Receptor 1 Correlates with Clinicopathological Parameters in Cutaneous Squamous Cell Carcinoma. Ann Dermatol (2009) 0.75
Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies. Laryngoscope (2016) 0.75
Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. Support Care Cancer (2017) 0.75
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet (2006) 6.67
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol (2005) 3.86
Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol (2009) 3.70
Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol (2007) 3.39
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol (2007) 3.06
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol (2008) 2.85
Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. J Mol Diagn (2012) 2.53
Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: a methodological study on lymph nodes from melanoma patients. J Mol Diagn (2003) 2.41
Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial. Radiother Oncol (2003) 2.32
Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiother Oncol (2008) 2.28
Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol (2003) 2.26
In vitro RBE-LET dependence for multiple particle types. Acta Oncol (2011) 2.18
Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol (2005) 2.10
Impact of delay on diagnosis and treatment of primary lung cancer. Acta Oncol (2002) 1.91
Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol (2009) 1.84
TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol (2005) 1.78
Does amifostine have a role in chemoradiation treatment? Lancet Oncol (2003) 1.73
Changes from 1992 to 2002 in the pretreatment delay for patients with squamous cell carcinoma of larynx or pharynx: a Danish nationwide survey from DAHANCA. Acta Oncol (2006) 1.63
Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol (2012) 1.57
Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol (2007) 1.56
Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol (2009) 1.55
Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas. Acta Ophthalmol Scand (2004) 1.54
Second primary cancers after adjuvant radiotherapy in early breast cancer patients: a national population based study under the Danish Breast Cancer Cooperative Group (DBCG). Radiother Oncol (2013) 1.54
Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. Cancer (2004) 1.53
Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer (2011) 1.53
Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck (2008) 1.49
Focal S100A4 protein expression is an independent predictor of development of metastatic disease in cystectomized bladder cancer patients. Eur Urol (2006) 1.49
Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother Oncol (2009) 1.48
Supraglottic carcinoma: patterns of failure and salvage treatment after curatively intended radiotherapy in 410 consecutive patients. Int J Radiat Oncol Biol Phys (2002) 1.46
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res (2009) 1.43
Treatment influencing down-staging in EORTC Melanoma Group sentinel node histological protocol compared with complete step-sectioning: a national multicentre study. Eur J Cancer (2011) 1.43
The nodal location of metastases in melanoma sentinel lymph nodes. Am J Surg Pathol (2009) 1.43
Loco-regional recurrence after mastectomy in high-risk breast cancer--risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiother Oncol (2006) 1.38
Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res (2011) 1.33
Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer (2008) 1.32
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics (2011) 1.32
Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol (2003) 1.30
Evaluation of objective measures of smoking status--a prospective clinical study in a group of head and neck cancer patients treated with radiotherapy. Acta Oncol (2003) 1.30
HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol (2009) 1.28
Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival. Acta Oncol (2010) 1.28
FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol (2012) 1.24
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res (2002) 1.23
Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys (2010) 1.23
Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol (2004) 1.20
Defensin-rich granules of human neutrophils: characterization of secretory properties. Biochim Biophys Acta (2002) 1.14
Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol (2004) 1.10
Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys (2006) 1.10
The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol (2011) 1.10
Localization of serglycin in human neutrophil granulocytes and their precursors. J Leukoc Biol (2004) 1.09
The challenges of comparing a clinically validated test to other methods. J Mol Diagn (2013) 1.09
Does variability in normal tissue reactions after radiotherapy have a genetic basis--where and how to look for it? Radiother Oncol (2002) 1.08
High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol (2008) 1.08
Cancer suspicion in general practice, urgent referral and time to diagnosis: a population-based GP survey and registry study. BMC Cancer (2014) 1.08
Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol (2008) 1.08
Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol (2003) 1.08
Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging (2008) 1.07
A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol (2008) 1.07
Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol (2005) 1.07
Identification of accurate reference genes for RT-qPCR analysis of formalin-fixed paraffin-embedded tissue from primary non-small cell lung cancers and brain and lymph node metastases. Lung Cancer (2013) 1.07
Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiother Oncol (2007) 1.06
Validity and representativity in the Danish Breast Cancer Cooperative Group--a study on protocol allocation and data validity from one county to a multi-centre database. Acta Oncol (2003) 1.06
The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol (2003) 1.05
Salvage laryngectomy and pharyngocutaneous fistulae after primary radiotherapy for head and neck cancer: a national survey from DAHANCA. Head Neck (2003) 1.04
Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer. PLoS One (2008) 1.04
Microarray analysis of the transcriptional response to single or multiple doses of ionizing radiation in human subcutaneous fibroblasts. Radiother Oncol (2005) 1.04
Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol (2003) 1.03
Salivary gland carcinoma in Denmark 1990-2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol (2011) 1.03
Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol (2011) 1.02
Long-term anorectal dysfunction after postoperative radiotherapy for rectal cancer. Dis Colon Rectum (2005) 1.01
ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.00
Papillary thyroid microcarcinoma in Denmark 1996-2008: a national study of epidemiology and clinical significance. Thyroid (2013) 1.00
Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFα prevents radiation-induced fibrosis. Radiother Oncol (2010) 0.99
Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer (2007) 0.99
Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials. Acta Oncol (2011) 0.99
A fatal case of malignant atrophic papulosis (Degos' disease) in a man with factor V Leinden mutation and lupus anticoagulant. Acta Derm Venereol (2006) 0.99
Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate (2004) 0.97
Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. Mol Oncol (2013) 0.97
Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer (2012) 0.97